Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 3/20 | 0.31 |
| ▸ | MC4R | P32245 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886350 | 0.90 | KCNH2 (0.32) | KCNH2 | |
| SCHEMBL5886261 | 0.89 | BRD4 (0.34) | KCNH2GRM5BRD4 | |
| SCHEMBL5886442 | 0.88 | KCNH2 (0.36) | KCNH2GRM5BRD4 | |
| SCHEMBL5886365 | 0.88 | KCNH2 (0.31) | KCNH2 | |
| SCHEMBL4155476 | 0.88 | ALOX5AP (0.32) | KCNH2GRM5BRD4 | |
| SCHEMBL5886360 | 0.87 | GRM5 (0.32) | KCNH2GRM5BRD4 | |
| SCHEMBL5886417 | 0.86 | KDM4E (0.34) | KCNH2GRM5BRD4 | |
| SCHEMBL5886337 | 0.86 | PDE10A (0.32) | KCNH2BRD4MC4R | |
| SCHEMBL5886372 | 0.85 | BRD4 (0.32) | KCNH2BRD4 | |
| SCHEMBL5886345 | 0.84 | PDCD1 (0.33) | KCNH2GRM5BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122546-B2 | Imidazol-1-ylmethyl pyridazine derivatives | NEUROGEN CORPORATION (US) | 2006-10-17 | — | — | US | claimed |
| EP-1549636-A1 | IMIDAZOL-1-YLMETHYL PYRIDAZINE DERIVATIVES | Neurogen Corporation (US) | 2005-07-06 | — | — | EP | claimed |
| US-20040077653-A1 | Imidazol-1-ylmethyl pyridazine derivatives | NEUROGEN CORPORATION | 2004-04-22 | — | — | US | claimed |
| WO-2004031174-A1 | IMIDAZOL-1-YLMETHYL PYRIDAZINE DERIVATIVES | NEUROGEN CORPORATION (US) | 2004-04-15 | — | — | WO | claimed |
| US-20090023737-A1 | Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands | NEUROGEN CORPORATION (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023737-A1 | Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands | NEUROGEN CORPORATION (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023737-A1 | Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands | NEUROGEN CORPORATION (US) | 2009-01-22 | — | — | US | disclosed |
| EP-1713784-A1 | IMIDAZO-PYRIDAZINES, TRIAZOLO-PYRIDAZINES AND RELATED BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2006-10-25 | — | — | EP | disclosed |
| US-7122546-B2 | Imidazol-1-ylmethyl pyridazine derivatives | NEUROGEN CORPORATION (US) | 2006-10-17 | — | — | US | disclosed |
| WO-2005080355-A1 | IMIDAZO-PYRIDAZINES, TRIAZOLO-PYRIDAZINES AND RELATED BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005080355-A1 | IMIDAZO-PYRIDAZINES, TRIAZOLO-PYRIDAZINES AND RELATED BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-1549636-A1 | IMIDAZOL-1-YLMETHYL PYRIDAZINE DERIVATIVES | Neurogen Corporation (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040077653-A1 | Imidazol-1-ylmethyl pyridazine derivatives | NEUROGEN CORPORATION | 2004-04-22 | — | — | US | disclosed |
| WO-2004031174-A1 | IMIDAZOL-1-YLMETHYL PYRIDAZINE DERIVATIVES | NEUROGEN CORPORATION (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023737-A1 | Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands | GABRA4, GABRA2, GABRA5 | KCNH2 461/4885GRM5 40/4885BRD4 534/4885 |
| US-20040077653-A1 | Imidazol-1-ylmethyl pyridazine derivatives | GABRA5, GABRA1, GABRA2 | KCNH2 885/4885GRM5 31/4885BRD4 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.